Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
MELANOMA: NEOADJUVANT: STAGE III: KEYNOTE U02-C

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C

Title
Merck MK-3475-U02C (Neoadjuvant Stage III)
Study Title

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C

Site Link
Malignancy
Melanoma, Cutaneous Melanoma
Stage
Disease Setting
Neoadjuvant; prior to definitive resection
Line Of Therapy
Neoadjuvant
Investigational Agent
Pembrolizumab, MK-7684, V937
Drug Class
Anti-PD-1, Anti-TIGIT, Oncolytic virus
PI
David Portnoy, MD
Sponsor
Merck Sharp & Dohme Corp
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Histologically or cytologically confirmed melanoma
  • Clinically detectable and resectable Stage IIIB, IIIC, or IIID melanoma
  • Has been untreated for the melanoma with the exception that primary lesion may have been resected or irradiated
  • No known CNS mets
  • No ocular or mucosal melanoma
  • No known HIV/HBV/HCV
  • No active autoimmune disease requiring therapy in past 2 years
  • Must not have received prior oncolytic viruses
Objective
  • Primary
    • pathCR
    • Safety
  • Secondary
    • Near pathCR
    • Path PR
    • RFS
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Melanoma
Dosing Frequency
Control Agents
Study Protocol
Randomized
Yes
X